Skip to content
Optellum
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales
Menu Close
  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

News & Events

AI breakthrough could speed up lung cancer diagnosis – and save the NHS millions

  • Post author:Rhiannon Lassiter
  • Post published:April 26, 2021
  • Post category:Media

MSN news has published a story about Optellum. Read the full article here.

Read more articles

Previous PostEIT Health supported Optellum in AI world-first
Next PostUK Health Tech Company, Goes Global With Breakthrough in Early Lung Cancer Diagnosis AI Technology

You Might Also Like

Read more about the article Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson, applying AI to transform early lung cancer treatment

Optellum announces strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson, applying AI to transform early lung cancer treatment

August 19, 2021
Read more about the article GE Healthcare-Optellum’s collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel’s Mammoscreen

GE Healthcare-Optellum’s collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel’s Mammoscreen

November 30, 2021
Read more about the article Lung health startup partners with Johnson & Johnson’s lung cancer initiative

Lung health startup partners with Johnson & Johnson’s lung cancer initiative

August 18, 2021
  • Back to News & Events

Recent Posts

  • How Optellum is working to change the survival rates for lung cancer with an innovative AI platform
  • Optellum welcomes ESTI back to Oxford for 2022 congress
  • PRESS RELEASE: CMS assigns new technology payment classification for Optellum’s Lung Cancer Prediction score
  • Optellum’s UK regulatory certification bolstered by UKCA marking for its early lung cancer diagnosis AI technology
  • Optellum is attending the 2022 ASCO Annual Meeting

Our Mission

Optellum was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, and cured.  Our vision is to redefine early intervention of diseases like lung cancer, by enabling every clinician, in every hospital, to make the right decisions and give their patients the best chance to fight back.

Optellum Ltd.

  • Oxford Centre for Innovation
    Oxford
    OX1 1BY
    United Kingdom
  • info@optellum.comOpens in your application

Optellum Inc.

  • TMC Innovation Institute
    2450 Holcombe Blvd, Suite X
    Houston, TX 77021
    United States

Follow Us

  • Opens in a new tab
  • Opens in a new tab

Pages

  • About us
    • Vision
    • Team
    • Advisors
    • Careers
  • Products & solutions
    • Incidental management
    • Lung Cancer Prediction AI
  • Resources
    • Case studies
    • Clinical Validation
    • Customer Support
  • News & Events
    • In the Media
  • Contact
    • General inquiries
    • Newsletter
    • Contact sales

Certifications

Copyright 2022 - Optellum Ltd | Privacy Policy
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}